Business Wire

MA-BLUECONIC

25.1.2024 13:59:34 CET | Business Wire | Press release

Share
VodafoneZiggo and BlueConic Win Platinum Award for Best Customer Data Platform Solution

Working with market-leading customer data platform (CDP) BlueConic, Dutch telecommunications company VodafoneZiggo has revolutionised its customer engagement strategies, resulting in a 17.6% increase in website interactions and a 4.53% reduction in churn. The collaboration has earned both companies a Platinum award for Best Customer Data Platform Solution in Juniper Research’s Future Digital Awards for Telco Innovation.

Presented by Juniper Research, the awards recognize the most innovative and disruptive telecommunications solutions operating across numerous areas. VodafoneZiggo has already won several awards for its dedication to data-driven decision-making and experimentation but knew it needed to unify its first-party customer data across numerous disparate systems and sources in order to boost engagement, deliver better customer experiences, and ultimately drive customer acquisition and retention. While some CDPs mostly focus on data unification and others tout personalization offerings, VodafoneZiggo is able to do both with BlueConic.

Leveraging the platform to understand customer preferences, easily segment their audiences, and target customers and households across channels with real-time data, VodafoneZiggo was able to transform its customer engagement strategy in several key areas:

  • Product recommendations: Using BlueConic, the conversion rate optimization (CRO) team can identify which operating system (OS) a customer is using while browsing their website. Knowing customers are likely to purchase the same type of phone again, they can personalize the shopping experience by only showing them phones with the same OS. For customers using a different OS, product recommendations dynamically update to show recently browsed devices. Within the first six months, this strategy drove a 3.5% increase in clickthrough for returning mobile visitors. On the B2B side of the business, they saw a 2.26% increase on product detail page visits and a 2.95% increase in add-to-carts. For B2C, there was a 17.6% increase in interactions for both new and returning visitors.
  • Targeting and personalization: VodafoneZiggo also leverages BlueConic to automatically send segments into custom audiences in Facebook – eliminating the need for manual uploads from their CRM system. Because segments update in real-time, ads are automatically suppressed for customers who have already purchased a new phone or renewed a subscription, thereby optimising their targeting efforts while increasing their return on ad spend (ROAS).
  • Churn prevention: By connecting churn probability scores from their Advanced Analytics department to BlueConic profiles, VodafoneZiggo can automatically route at-risk customers to chat with customer support specialists online. This strategy resulted in a 4.53% reduction in churn, a 7.14% increase in chats, and decreased web-to-call by 7.14%.

“While we’re no stranger to winning awards, it’s even more rewarding when we can share that recognition with our customers to celebrate their success,” said Ifoma Smart, VP of Global Customer Success at BlueConic. “When it comes to innovation, technology is just one part of the puzzle. You also need strong processes and a skilled and talented team – attributes VodafoneZiggo has in abundance. They quickly discovered BlueConic not only provides a better way to access and utilize first-party data to drive customer engagement but also offers the flexibility to grow with their business. We’re delighted their success with our customer data platform has been recognized by the esteemed analysts at Juniper Research.”

About Juniper Research

Juniper Research provides research and analytical services to the global hi-tech communications sector; providing consultancy, analyst reports and industry commentary.

About Juniper Research’s Future Digital Awards

Since 2008, the Future Digital Awards have honoured the companies leading innovation and disruption in their respective markets. Winners of the awards are known for developing and implementing groundbreaking products and solutions that have the potential to disrupt their ecosystem, whilst providing substantial benefits to consumers and the wider industry.

About BlueConic

BlueConic, the leading pure-play customer data platform, liberates companies’ first-party data from disparate systems and makes it accessible wherever and whenever it is required to transform customer relationships and drive business growth. Over 350 companies worldwide, including Forbes, Heineken, Mattel, Michelin, Telia Company, and VF Corp, use BlueConic to unify data into persistent, individual- profiles, and then activate it across customer touchpoints and systems in support of a wide range of growth-focused initiatives, including customer lifecycle orchestration, modeling and analytics, digital products and experiences, audience-based monetization, and more. Learn more at www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240125760576/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye